Atlas Trials

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Clinical trial NCT06911606 · RECRUITING

Trial details

NCT number
NCT06911606
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
SCLC, Limited Stage
Start date
2024-05-22
Primary completion
2026-06-30
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.